SmartMed Technologies of Seoul today announced they it will host a conference to highlight the latest research in tumor mutation.
Online PR News – 16-July-2020 – YEONGDEUNGPO-GU/SEOUL – SmartMed Technologies’ clinical research data will focus on the research and development of applications in order to target certain immunotherapies.
SmartMed Technologies have invested heavily in this rapidly evolving field of research using artificial intelligence to detect experiments across 150 tumor-related genes.
SmartMed Technologies' Chief Medical Officer, Dr. Norman Hammond commented on the research saying “We have to design and develop certain tumor mutation solutions to assess and characterize certain tumors. Our ultimate aim is to drive adoption of next-generation sequencing using clinical research panels designed to help identify how to treat tumors.”
"We are developing a meticulous method to characterize and assess tumor mutation which is of paramount importance for future applications in emerging biotechnology and medical science,” added Dr. Norman Hammond, Chief Medical Officer of SmartMed Technologies.
About Us - SmartMed Technologies
SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.
Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.
With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.
With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.